Payment overview · 2025
General Payments
$1,091.06
43 reported records · 9 companies
Healthcare provider profile · identity verified
Susan M Jackson, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · UTICA, NY · NPI 1699889949
Verified facts
What the public records show
CMS Open Payments records show Susan M Jackson, FNP received $1,091.06 in general payments during 2025 across 43 reported records.
Novo Nordisk Inc accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $300.80 | 27.6% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $199.63 | 18.3% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $166.29 | 15.2% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $144.93 | 13.3% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $123.05 | 11.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.98 | 6.5% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $49.33 | 4.5% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $22.36 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.69 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,091.06 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $300.80 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $189.55 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $166.29 | 11 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $123.05 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $104.74 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $70.98 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $49.33 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.19 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.98 | 3 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $10.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 27 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 436 | 133 |
| Omeprazole | Omeprazole | 356 | 93 |
| Lisinopril | Lisinopril | 353 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 65 |
| Metformin Hcl | Metformin Hcl | 248 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 67 |
| Gabapentin | Gabapentin | 233 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 53 |
| Simvastatin | Simvastatin | 158 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 44 |
| Allopurinol | Allopurinol | 129 | 38 |
| Furosemide | Furosemide | 127 | 29 |
| Losartan Potassium | Losartan Potassium | 124 | 44 |
| Ezetimibe | Ezetimibe | 120 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 27 |
| Meloxicam | Meloxicam | 109 | 31 |
| Sertraline Hcl | Sertraline Hcl | 106 | 28 |
| Eliquis | Apixaban | 101 | 20 |
| Montelukast Sodium | Montelukast Sodium | 100 | 23 |
| Alprazolam | Alprazolam | 98 | 25 |
| Famotidine | Famotidine | 97 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 23 |
| Potassium Chloride | Potassium Chloride | 92 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 27 |
| Trazodone Hcl | Trazodone Hcl | 88 | 24 |
| Ozempic | Semaglutide | 83 | 17 |
| Metformin Hcl Er | Metformin Hcl | 80 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 18 |
| Buspirone Hcl | Buspirone Hcl | 76 | 20 |
| Alendronate Sodium | Alendronate Sodium | 73 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 21 |
| Mirtazapine | Mirtazapine | 67 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 16 |
| Atenolol | Atenolol | 65 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 24 |
| Clonidine Hcl | Clonidine Hcl | 63 | 15 |
| Carvedilol | Carvedilol | 61 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 15 |
| Prednisone | Prednisone | 57 | 39 |
| Januvia | Sitagliptin Phosphate | 56 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 13 |
| Jardiance | Empagliflozin | 55 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 11 |
| Nystatin | Nystatin | 47 | 20 |
| Glipizide | Glipizide | 46 | 12 |
| Azithromycin | Azithromycin | 45 | 32 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Glipizide Er | Glipizide | 45 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Sucralfate | Sucralfate | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 12 |
| Celecoxib | Celecoxib | 43 | 13 |
| Ibuprofen | Ibuprofen | 43 | 12 |
| Meclizine Hcl | Meclizine Hcl | 43 | 12 |
| Tramadol Hcl | Tramadol Hcl | 43 | 11 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Xanax | Alprazolam | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,091.06 · 43 records | Novo Nordisk Inc | AREXVY, BREZTRI, FARXIGA, NUCALA, Ohtuvayre, Ozempic, Prolastin-C Liquid, Rybelsus, TRELEGY ELLIPTA, TREMFYA, VOQUEZNA, VRAYLAR, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error